Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Lymphoma

lutetium has been researched along with Lymphoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azorín-Vega, E; Ferro-Flores, G; Jiménez-Mancilla, N; Martínez-Ventura, B; Ordaz-Rosado, D; Ramos-Bernal, J; Rojas-Calderón, E; Serrano-Espinoza, L1
Bäck, TA; Booth, GC; Fisher, DR; Frayo, SL; Frost, SH; Gopal, AK; Green, DJ; Hylarides, MD; Lin, Y; Miller, BW; Orozco, JJ; Pagel, JM; Press, OW1
Banerjee, S; Das, T; Mishra, KP; Sarma, HD; Venkatesh, M; Vidyasagar, PB1
Boerman, OC; Corstens, FH; Frielink, C; Goldenberg, DM; Oyen, WJ; Postema, EJ; Raemaekers, JM1
Anderson, TL; Arterburn, JB; Erion, J; Larson, RS; Norenberg, JP; Poria, RB; Wagner, CR1

Other Studies

5 other study(ies) available for lutetium and Lymphoma

ArticleYear
Assessment of cell death mechanisms triggered by
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2018, Volume: 138

    Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Radiation; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Humans; Immunoconjugates; Lutetium; Lymphoma; Radioimmunotherapy; Radioisotopes; Rituximab

2018
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Animals; Antigens, CD20; Beta Particles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Immunoconjugates; Lutetium; Lymphoma; Mice; Mice, Nude; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2015
Studies on efficacy of a novel 177Lu-labeled porphyrin derivative in regression of tumors in mouse model.
    Current radiopharmaceuticals, 2011, Volume: 4, Issue:2

    Topics: Animals; Female; Fibrosarcoma; Lutetium; Lymphoma; Mice; Neoplasms, Experimental; Porphyrins; Radioisotopes; Radiopharmaceuticals; Thymus Neoplasms; Tissue Distribution

2011
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:4

    Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Duodenum; Female; Femur; Humans; Iodine Radioisotopes; Kidney; Lectins; Liver; Lung; Lutetium; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Muscles; Neoplasm Transplantation; Neoplasms; Radioimmunotherapy; Radioisotopes; Rhenium; Sialic Acid Binding Ig-like Lectin 2; Spleen; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2003
Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia.
    Cancer biotherapy & radiopharmaceuticals, 2006, Volume: 21, Issue:5

    Topics: Animals; Binding, Competitive; Heterocyclic Compounds, 1-Ring; HL-60 Cells; Humans; Hydantoins; Imidazolidines; Isotope Labeling; Kinetics; Leukemia; Lutetium; Lymphocyte Function-Associated Antigen-1; Lymphoma; Mice; Molecular Structure; Organometallic Compounds; Radioisotopes; Radionuclide Imaging

2006